Shares of Inspira Technologies OXY B.H.N. Ltd (NASDAQ:IINN) rose 5.1% in premarket trading on Thursday after the company set out a strategic roadmap to expand into liquid biopsy diagnostics while continuing to protect and develop its core respiratory technology business.
The Ra’anana-based developer of life-support and diagnostic technologies said its strategy includes a proposed acquisition of an advanced liquid biopsy platform, paired with a simultaneous equity investment. Inspira explained that the structure of the transaction is intended to allow for future dividend distributions generated by its established respiratory and life-support operations.
Management described the move into liquid biopsy as a “natural and execution-ready” extension of Inspira’s existing expertise in blood-based diagnostics and real-time monitoring. The company highlighted its proprietary HYLA blood sensor platform, which has demonstrated accuracy levels ranging from 95% to 99% across measured parameters during clinical testing.
“The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira, adding a high-impact diagnostics capability with substantial long-term potential,” said Tal Parnes, Chairman of Inspira’s Board.
Inspira also noted that it has already set up a dedicated blood diagnostics laboratory to support expansion into adjacent diagnostic fields, including oncology. In addition, the company pointed to its familiarity with U.S. regulatory processes, citing the FDA 510(k) clearance of its ART100 system as evidence of its ability to guide new diagnostic technologies through regulatory approval and into commercialization.